https://www.selleckchem.com/products/yo-01027.html
20, 95% CI 0.09-0.43), and a trend for lower VTE risk compared with Hickman catheters (OR = 0.75, 95% CI 0.37-1.5. Meta-regression models suggested that regional difference may significantly impact on the incidence of VTE associated with TIVAPs. Conclusions Current evidence suggests that the cancer patients with TIVAP are less likely to develop VTE compared with external CVCs. This should be considered when choosing the indwelling intravenous device for chemotherapy. However, more attention should be paid when choosing upper-extremit
Like
Comment
Share
